Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TXG
BUY10x Genomics, Inc. · Healthcare · United States · $5.9B · Avg Vol: $154M/d
COMPANY DESCRIPTION
10x Genomics, Inc. develops and sells integrated systems, including instruments, consumables, and software, for advanced genomic analysis, specializing in single-cell and spatial biology. The company's competitive moat is derived from its proprietary technology platforms, which provide unprecedented resolution in biological research, establishing it as a market leader in these rapidly expanding fields. 10x Genomics is a key enabler for breakthroughs in genomics and biomedical discovery.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 516.4M | 618.7M | 610.8M | 642.8M | 7.6% | 638.8M | 614.1M | 671.5M | 2.2% |
| EPS | -1.46 | -2.18 | -1.52 | -0.35 | — | -0.17 | — | — | — |
| Shares | 115.2M | 119.1M | 122.3M | 127.7M | +10.8% | 116.9M | — | — | — |
| Debt | 95.2M | 95.4M | 82.6M | 84.4M | -3.9% | 81.4M | — | — | — |
| Equity | 805.7M | 741.0M | 710.1M | 796.3M | -0.4% | — | — | — | — |
| Op CF | -33.6M | -15.2M | 6.7M | 136.1M | 1941.6% | 127.8M | — | — | — |
| Inv CF | -350.9M | 133.5M | -32.6M | -13.4M | — | — | — | — | — |
| Fin CF | 15.8M | 13.7M | 10.9M | 6.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TXG are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TXG | 10x Genomics, Inc.(you) | $5.9B | 75 | BUY |
| HNGE | Hinge Health, Inc. | $5.8B | 81 | STRONG BUY |
| HQY | HealthEquity, Inc. | $7.9B | 84 | STRONG BUY |
| WAY | Waystar Holding Corp. | $4.3B | 64 | HOLD |
| DOCS | Doximity, Inc. | $3.7B | 62 | HOLD |
| TDOC | Teladoc Health, Inc. | $1.6B | 76 | BUY |
| PRVA | Privia Health Group, Inc. | $3.2B | 59 | HOLD |
| OMCL | Omnicell, Inc. | $1.9B | 65 | BUY |
| BTSG | BrightSpring Health Services, Inc. | $14.3B | 91 | STRONG BUY |
| VEEV.MX | Veeva Systems Inc. | $27.6B | 71 | BUY |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.5%